Determinants of MASLD and liver fibrosis in maintenance hemodialysis: a prospective evaluation of metabolic, nutritional, and volume-related factors.
- 1Department of Nephrology, School of Medicine, Recep Tayyip Erdogan University, Rize, Türkiye.
- 2Department of Gastroenterology, School of Medicine, Recep Tayyip Erdogan University, Rize, Türkiye.
- 3Department of Nephrology, School of Medicine, Recep Tayyip Erdogan University, Rize, Türkiye. [email protected].
Abstract
Background & aims
Metabolic dysfunction associated steatotic liver disease (MASLD) is underrecognized in hemodialysis (HD) patients, yet its evaluation is confounded by volume fluctuations. We aimed to determine the prevalence of MASLD and advanced fibrosis using transient elastography (TE), identify their metabolic, nutritional, and volume-related determinants, and assess the impact of a single HD session on controlled attenuation parameter (CAP) and liver stiffness measurement (LSM).Methods
Forty adult patients on maintenance HD for ≥ 3 months were enrolled in this prospective cross-sectional study. TE was performed immediately before and after a midweek dialysis session. Steatosis was defined as CAP > 257 dB/m and advanced fibrosis as LSM ≥ 8 kPa. Volume status was assessed by interdialytic weight gain (IDWG) and ultrafiltration (UF) volume. Associations with clinical, biochemical, and dialysis-related variables were analyzed.Results
The study cohort had a mean age of 63.5 ± 17.3 years, with males comprising 70% and diabetic patients accounting for 30% of the population. MASLD prevalence was 25% pre-HD and 22.5% post-HD; advanced fibrosis prevalence was 17.5% pre-HD and 10% post-HD. CAP and LSM did not change significantly with fluid removal (p = 0.877 and p = 0.962, respectively). CAP correlated positively with body mass index, IDWG, UF volume, and triglycerides, and negatively with serum albumin. Post-HD LSM showed a strong inverse association with serum albumin and positive associations with alanine aminotransferase, total cholesterol, and LDL-cholesterol, whereas pre-HD LSM was predominantly linked to age and bilirubin. The FIB-4 index did not correlate with LSM.Conclusions
MASLD and advanced fibrosis are highly prevalent in maintenance HD patients. TE provides a clinically valuable, volume-independent assessment of liver disease, outperforming FIB-4 in this setting. Low albumin and dyslipidemia emerge as key correlates of fibrosis, highlighting the interplay between malnutrition, metabolic risk, and liver stiffness in end-stage renal disease.
Related
- Changes in Nutritional Status and Bioimpedance Parameters During EAA/KA Supplementation in Elderly Patients Undergoing Maintenance Hemodialysis: A Retrospective Observational Study
- Predictors of Cardiovascular Events in Patients Undergoing Maintenance Hemodialysis for Diabetic Kidney Disease: A Two-year Prospective Cohort Study
- Plasma Osteoprotegerin and Cardiovascular Mortality During the First Two Years of Maintenance Hemodialysis: A Prospective Observational Cohort Study.
- Predictors of physical performance decline in patients receiving maintenance hemodialysis: a prospective observational study
- Development of a nomogram for identifying prevalent medication discrepancy in maintenance hemodialysis patients: a multicenter cross-sectional study
BibTeX
@article{koc2026determinants,
title = {{Determinants of MASLD and liver fibrosis in maintenance hemodialysis: a prospective evaluation of metabolic, nutritional, and volume-related factors.}},
author = {Leyla Koc and Caglayan Keklikkiran and Remzi Adnan Akdogan and Ekrem Kara},
journal = {Diabetology \& metabolic syndrome},
year = {2026},
month = aug,
doi = {10.1186/s13098-026-02260-7},
url = {https://europepmc.org/article/MED/42958584},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Determinants of MASLD and liver fibrosis in maintenance hemodialysis: a prospective evaluation of metabolic, nutritional, and volume-related factors.
AU - Leyla Koc
AU - Caglayan Keklikkiran
AU - Remzi Adnan Akdogan
AU - Ekrem Kara
PY - 2026
DA - 2026/08/03
JO - Diabetology & metabolic syndrome
DO - 10.1186/s13098-026-02260-7
UR - https://europepmc.org/article/MED/42958584
AB - Background & aims Metabolic dysfunction associated steatotic liver disease (MASLD) is underrecognized in hemodialysis (HD) patients, yet its evaluation is confounded by volume fluctuations. We aimed to determine the prevalence of MASLD and advanced fibrosis using transient elastography (TE), identify their metabolic, nutritional, and volume-related determinants, and assess the impact of a single HD session on controlled attenuation parameter (CAP) and liver stiffness measurement (LSM).Methods Forty adult patients on maintenance HD for ≥ 3 months were enrolled in this prospective cross-sectional study. TE was performed immediately before and after a midweek dialysis session. Steatosis was defined as CAP > 257 dB/m and advanced fibrosis as LSM ≥ 8 kPa. Volume status was assessed by interdialytic weight gain (IDWG) and ultrafiltration (UF) volume. Associations with clinical, biochemical, and dialysis-related variables were analyzed.Results The study cohort had a mean age of 63.5 ± 17.3 years, with males comprising 70% and diabetic patients accounting for 30% of the population. MASLD prevalence was 25% pre-HD and 22.5% post-HD; advanced fibrosis prevalence was 17.5% pre-HD and 10% post-HD. CAP and LSM did not change significantly with fluid removal (p = 0.877 and p = 0.962, respectively). CAP correlated positively with body mass index, IDWG, UF volume, and triglycerides, and negatively with serum albumin. Post-HD LSM showed a strong inverse association with serum albumin and positive associations with alanine aminotransferase, total cholesterol, and LDL-cholesterol, whereas pre-HD LSM was predominantly linked to age and bilirubin. The FIB-4 index did not correlate with LSM.Conclusions MASLD and advanced fibrosis are highly prevalent in maintenance HD patients. TE provides a clinically valuable, volume-independent assessment of liver disease, outperforming FIB-4 in this setting. Low albumin and dyslipidemia emerge as key correlates of fibrosis, highlighting the interplay between malnutrition, metabolic risk, and liver stiffness in end-stage renal disease.
SN - 1758-5996
ER -